Table 1.
Demographic, behavioral, and clinical characteristics (Data set 1)
| Schizophrenia (n = 41) | Comparison group (n = 41) | Between‐group comparison | |
|---|---|---|---|
| Sex (male/female) | 28/13 | 24/17 | χ2(1, N = 82) = 0.97, p = 0.32 |
| Age (years) | 40.9 ± 10.0 | 38.3 ± 10.5 | t(82) = 1.1, p = 0.27 |
| Illness duration (years) | 17.9 ± 9.3 | – | – |
| IQ (WASI) | 86.1 ± 18.7 | 111.2 ± 13.6 | t(75) = 6.70, p < 0.01* |
| Education (years) | 12.0 ± 0.55 | 16.4 ± 0.47 | t(79) = −6.35, p < 0.01* |
| GAF | 45.9 ± 13.0 | 79.5 ± 10.6 | t(79) = −12.79, p < 0.01* |
| SOFAS | 46.5 ± 14.8 | 79.5 ± 11.0 | t(80) = −11.49, p < 0.01* |
| Generalized cognition1 (CANTAB) | −48.5 ± 30.2 | 42.9 ± 20.7 | t(82) = 7.91, p < 0.01* |
| Clozapine dosage (mg/day) | 393.24 ± 24.6 | – | – |
| Chlorpromazine equivalent dosage (mg/day) | 615.4 ± 55.84 | – | – |
| SAPS2 | 1.19 ± 0.62 | – | – |
| SANS2 | 1.48 ± 0.79 | – | – |
Note. IQ = intelligence quotient; WASI = Wechsler abbreviated scale of intelligence; GAF = the global assessment of functioning; SOFAS = social and occupational functioning assessment scale; CANTAB = Cambridge neuropsychological test automated battery; SAPS = scale for the assessment of positive symptoms; SANS = scale for the assessment of negative symptoms; mg = milligram.
Significant p < 0.01. Mean ± standard deviation of each measure is shown.
Principal component across multiple CANTAB outcome measures (Section 2.8, Supporting Information Table S2).
Mean across all available subscales (Section 2.8, Supporting Information Table S2). Variation in degrees of freedom is due to missing data for some individuals.